The Trump administration is considering Dr. Norman Sharpless, a former National Cancer Institute director, for the role of FDA chief. Sharpless, who has expressed concerns about recent FDA vaccine policies, is among several candidates being vetted for the position. His previous tenure as acting FDA commissioner in 2019 could provide valuable experience for stabilizing the agency amid recent upheavals.

Background and Qualifications

Dr. Sharpless led the National Cancer Institute throughout President Trump’s first term and part of the Biden administration before leaving government in 2022. He is currently a professor at the University of North Carolina School of Medicine and co-founded a venture capital fund focused on biotechnology. Sharpless has been vocal about his concerns regarding FDA’s vaccine safety policies, signing a letter with other former FDA leaders opposing changes they believe undermine vaccine safety and availability.

Political Context

This consideration marks a shift from the administration’s previous alignment with the “Make America Healthy Again” movement, led by Health and Human Services Secretary Robert F. Kennedy Jr. The movement has seen its influence decline as the administration seeks more conventional leadership to address perceived weaknesses in health department operations.

Other candidates under consideration include Richard Pops, a pharmaceutical executive, and acting FDA commissioner Kyle Diamantas. Diamantas, while respected for his work on food policies, lacks experience in drug issues, which may impact his candidacy.

Challenges Ahead

The selection process is ongoing, with the administration aiming to present a nominee to President Trump soon. The chosen candidate will need to navigate a closely divided Senate for confirmation, where issues such as access to the abortion pill mifepristone could become contentious. Sharpless previously supported the FDA’s scientific decisions on mifepristone access, which may influence his confirmation prospects.

The administration is also working to strengthen ties with key GOP senators to facilitate the confirmation process. This includes outreach to Sen. Bill Cassidy, who has had a contentious relationship with Kennedy but remains influential in advancing health department nominees.

Original reporting: El Paso News (HLL/CB) — read the source article.